Sotac Pharmaceuticals Ltd
Incorporated in 2015, Co. is in the business of manufacturing pharmaceutical products for different marketers on a loan license or contract manufacturing basis[1]
- Market Cap ₹ 137 Cr.
- Current Price ₹ 124
- High / Low ₹ 155 / 97.0
- Stock P/E 31.1
- Book Value ₹ 41.0
- Dividend Yield 0.00 %
- ROCE 14.1 %
- ROE 22.6 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.02 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 29 | 49 | 77 | 104 | |
| 27 | 47 | 70 | 95 | |
| Operating Profit | 2 | 1 | 7 | 8 |
| OPM % | 7% | 3% | 9% | 8% |
| 0 | 0 | 1 | 0 | |
| Interest | 0 | 1 | 2 | 2 |
| Depreciation | 1 | 3 | 2 | 3 |
| Profit before tax | 0 | -2 | 4 | 4 |
| Tax % | 75% | -15% | 42% | 10% |
| 0 | -2 | 2 | 4 | |
| EPS in Rs | 0.39 | -10.30 | 2.84 | 3.87 |
| Dividend Payout % | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 29% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 57% |
| TTM: | 124% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 |
| Reserves | 1 | 0 | 11 | 34 |
| 13 | 17 | 22 | 25 | |
| 14 | 15 | 32 | 35 | |
| Total Liabilities | 30 | 35 | 74 | 105 |
| 16 | 17 | 26 | 36 | |
| CWIP | -0 | -0 | 0 | 5 |
| Investments | 0 | 0 | -0 | 2 |
| 14 | 18 | 48 | 63 | |
| Total Assets | 30 | 35 | 74 | 105 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 0 | -0 | 8 | ||
| -12 | -3 | -12 | ||
| 11 | 3 | 13 | ||
| Net Cash Flow | -0 | -0 | 10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | |
| Inventory Days | 40 | 45 | 87 | |
| Days Payable | 194 | 121 | 162 | |
| Cash Conversion Cycle | -66 | -32 | -5 | |
| Working Capital Days | 14 | 15 | 28 | |
| ROCE % | -5% |
Business Verticals
A) Manufacturing of Non-Beta-Lactam Medicines and Formulations [1]
It manufactures Non-Beta-Lactam (general) tablets, Non-Beta-Lactam (general) capsules, oral liquid, dry syrup, and external preparations such as Ointment, Lotion, and cream and caters to 162 corporate clients on a loan license and/or contract manufacturing basis